Evidence map›Paper›PMID 28245556›Full record

ArticleInternational journal of molecular sciences2017

Supercritical-Carbon Dioxide Fluid Extract from Chrysanthemum indicum Enhances Anti-Tumor Effect and Reduces Toxicity of Bleomycin in Tumor-Bearing Mice.

Hong-Mei Yang, Chao-Yue Sun, Jia-Li Liang, Lie-Qiang Xu, Zhen-Biao Zhang, Dan-Dan Luo, Han-Bin Chen, Yong-Zhong Huang, Qi Wang, David Yue-Wei Lee and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 32 citations in OpenAlex.

  1. Prevention of supercritical carbon dioxide fluid extract fromExperimental and therapeutic medicine · 2024
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Chemically-Induced DNA Damage, Mutagenesis, and Cancer.International journal of molecular sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Hong-Mei YangGuangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. yanghongmei326@gmail.com.
Chao-Yue SunGuangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. yuhongl0822@gmail.com.
Jia-Li LiangGuangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. xing623853793@gmail.com.
Lie-Qiang XuGuangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. xulieqiang123@gmail.com.
Zhen-Biao ZhangGuangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. Lauyh0822@gmail.com.
Dan-Dan LuoGuangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. zhuojiany38193@gmail.com.
Han-Bin ChenGuangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. chenhanbin999@gmail.com.
Yong-Zhong HuangGuangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. jakin3305@gmail.com.
Qi WangGuangdong New South Artepharm, Co., Ltd., Guangzhou 510006, China. l1393318376@gmail.com.
David Yue-Wei LeeDepartment of McLean Hospital, Harvard Medical School, Belmont, CA 02478-9106, USA. ywlee228@gmail.com.
Jie YuanGuangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. yuanjie@gzucm.edu.cn.
Yu-Cui LiGuangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. liyucui@gzucm.edu.cn.
Guangzhou University of Chinese Medicine · CNMcLean Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bleomycin (BLM), a family of anti-tumor drugs, was reported to exhibit severe side effects limiting its usage in clinical treatment. Therefore, finding adjuvants that enhance the anti-tumor effect and reduce the detrimental effect of BLM is a prerequisite.

Indexed as

AnimalsAntibiotics, AntineoplasticApoptosisBleomycinCarbon DioxideCaspase 3Caspase 8Cell Line, TumorChrysanthemumCytokinesDisease Models, AnimalDrug SynergismFibrosisLiquid-Liquid ExtractionLungMiceAntibiotics, AntineoplasticBleomycinCarbon DioxideCaspase 3Caspase 8CytokinesMicroRNAsMIRN29a microRNA, humanPlant ExtractsTransforming Growth Factor beta1Tumor Suppressor Protein p53anti-tumor effectBLMpulmonary fibrosissupercritical-carbon dioxide fluid of C. indicum (CISCFE)synergism effect

Identifiers

PMID28245556
PMCPMC5372490
OpenAlexW2591313075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.